Approval · Notice of Compliance 36962 · 2026
NRA-RISPERIDONE: Notice of Compliance 36962
Issued February 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 36962
- Date
- February 24, 2026
- Company
- Nora Pharma Inc.Varennes, Quebec, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Admin
- Reason
- Administrative: Licensing Agreement between two manufacturers
- Canadian reference product
- RISPERDAL (Janssen-Ortho Inc.)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| NRA-RISPERIDONE | 02565994 | Approved |
| NRA-RISPERIDONE | 02566028 | Approved |
| NRA-RISPERIDONE | 02566036 | Approved |
| NRA-RISPERIDONE | 02566044 | Approved |
| NRA-RISPERIDONE | 02566060 | Approved |
| NRA-RISPERIDONE | 02566087 | Approved |
Medicinal ingredients
- RISPERIDONE 0.25 MG per TAB
- RISPERIDONE 0.5 MG per TAB
- RISPERIDONE 1 MG per TAB
- RISPERIDONE 2 MG per TAB
- RISPERIDONE 3 MG per TAB
- RISPERIDONE 4 MG per TAB